12409326

Source:http://linkedlifedata.com/resource/pubmed/id/12409326

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0034656, umls-concept:C0205179, umls-concept:C0205390, umls-concept:C0684249, umls-concept:C1514162
pubmed:issue	21
pubmed:dateCreated	2002-10-31
pubmed:abstractText	To evaluate whether two commonly used newer platinum-based regimens offer any advantage over vinorelbine-cisplatin (reference regimen) in response rate for patients with advanced non-small-cell lung cancer (NSCLC).
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin, http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel, http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine, http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine, http://linkedlifedata.com/resource/pubmed/chemical/vinorelbine
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	0732-183X
pubmed:author	pubmed-author:AdamsRR, pubmed-author:AltavillaGG, pubmed-author:BondHH, pubmed-author:CeribelliAA, pubmed-author:ClericiMM, pubmed-author:CrinòLL, pubmed-author:De MarinisFF, pubmed-author:Di CostanzoFF, pubmed-author:FaillaGG, pubmed-author:FrontiniLL, pubmed-author:GridelliCC, pubmed-author:Italian Lung Cancer Project, pubmed-author:MarangoloMM, pubmed-author:MatanoEE, pubmed-author:RicciSS, pubmed-author:RinaldiMM, pubmed-author:ScagliottiG VGV, pubmed-author:TonatoMM
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	20
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	4285-91
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:12409326-Adult, pubmed-meshheading:12409326-Aged, pubmed-meshheading:12409326-Aged, 80 and over, pubmed-meshheading:12409326-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12409326-Carboplatin, pubmed-meshheading:12409326-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:12409326-Cisplatin, pubmed-meshheading:12409326-Deoxycytidine, pubmed-meshheading:12409326-Disease Progression, pubmed-meshheading:12409326-Female, pubmed-meshheading:12409326-Humans, pubmed-meshheading:12409326-Infusions, Intravenous, pubmed-meshheading:12409326-Lung Neoplasms, pubmed-meshheading:12409326-Male, pubmed-meshheading:12409326-Middle Aged, pubmed-meshheading:12409326-Neutropenia, pubmed-meshheading:12409326-Paclitaxel, pubmed-meshheading:12409326-Survival Analysis, pubmed-meshheading:12409326-Thrombocytopenia, pubmed-meshheading:12409326-Treatment Outcome, pubmed-meshheading:12409326-Vinblastine
pubmed:year	2002
pubmed:articleTitle	Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
pubmed:affiliation	Department of Clinical and Biological Sciences, University of Torino, Turin. scagliotti@ihnet.it
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III